Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai Discontinues Promotion of Zonegran in the US
March 14, 2011
- Cervarix in Short Supply
March 14, 2011
- Eisai Postpones NHI Price Listing, Launching of NerBlock
March 14, 2011
- New Drugs Improve Range of Options for Osteoporosis: 4
March 14, 2011
- Eli Lilly Japan Posts Record-High Sales of ¥134,471 Mil. in 2010
March 14, 2011
- Wholesalers Wither, While Makers Thrive - Effects of New NHI Pricing System?
March 14, 2011
- Sawai to Terminate Negotiations with Kyorin
March 14, 2011
- Japan's Ethical Drug Market Grew 0.2% in 2010: IMS Japan
March 14, 2011
- Ranbaxy to Market Levofloxacin, Ofloxacin in Singapore: Daiichi Sankyo
March 14, 2011
- Takeda Licenses PDE1 Inhibitors from ITI
March 14, 2011
- Japan's Biosimilars Market Has Strong Growth Potential: Mr George of Sandoz
March 14, 2011
- Terumo Acquires CaridianBCT for US$2.6 Bil.
March 14, 2011
- New Drugs Improve Range of Options for Osteoporosis: 3
March 7, 2011
- PIII Results for Afinitor Published in NEJM
March 7, 2011
- Korosho Approves Norspan, NorLevo after One-Month Delay
March 7, 2011
- Avastin Prolongs PFS in Ovarian Cancer
March 7, 2011
- Nesina Approved for Coadministration with SU and BG: Takeda
March 7, 2011
- JAMS Announces GLs for COI Management
March 7, 2011
- Xeloda Approved for Advanced/Recurrent Stomach Cancer: Chugai
March 7, 2011
- 8 Companies to Withdraw Generic Versions of Dasen
March 7, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…